About Drug Discovery Today

Scope of journal: Drug Discovery Today is one of the most cited review journals in the field of drug discovery. Since its launch in 1996, it continues to publish reviews of key scientific and strategic issues as well as features, such as opinionated Editorials, interviews with international experts and business trends. Drug Discovery Today covers not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Drug Discovery Today is published monthly in print and updated daily on-line on ScienceDirect. Our current ISI impact factor is 7.7.

In 2004, the Drug Discovery Today journal series expanded with the launch of four online-only review journals: Drug Discovery Today: Disease Mechanisms, Drug Discovery Today: Disease Models, Drug Discovery Today: Therapeutic Strategies and Drug Discovery Today: Technologies. More information on these journals can be found by clicking on the button “Online Only Titles”

Article Types:
Each issue contains a short front section and review articles. The majority of the journal content can be found in the review section.

• Keynote reviews and Foundation reviews: These are comprehensive review articles which deal with a particular theme in great depth and are intended to provide a broad authoritative coverage of various fields.
• Short reviews: These are short review articles, which deal with focused topics and are categorised as:
  Gene-to-screen, which deals with the earliest part of drug discovery and all aspects involved in target identification, validation and assay development.
  Informatics, which deals with all aspects of computational biology and chemistry related to drug discovery.
  Post screen, which covers all of the science from hit identification to candidate selection and occasionally clinical trial design and patent issues.

The following article types are featured in the front section:

• Editorial: Opinionated articles intended to stimulate debate around a topic of interest to those involved in drug discovery.
• Interview: An interview with a leading figure in drug discovery or a related discipline.
• Biotech focus: This article type highlights the biotechnology capabilities of particular geographic locations.
• Business trends: Experts from PharmaProjects review trends in the approaches to treat disease classes.

There is a short section called Monitor, which highlights recent developments in medicinal chemistry and finally a Diary section which points readers to the most appropriate future conferences in drug discovery.

Editorial Staff:

Editor, S.L. Carney
Senior Editor, U. Knies-Bamforth
Acting Senior Editor: Sian Bithell
Content Development Manager: Jacky Smith
E-mail: DDT@drugdiscoverytoday.com

Advisory Editorial Board:

Jürgen Bajorath University of Bonn, Bonn, Germany
Walter Blackstock Experimental Therapeutics Centre,Singapore
David Brayden University College Dublin, Dublin, Ireland
Paul Caron Vertex Pharmaceuticals, Cambridge, USA
David Cavalla Arachnova, Cambridge, UK
David Clark  Argenta Discovery, Harlow, UK
Dalia Cohen Rosetta Genomics, North Brunswick, USA
Donald Daley Argenta Discovery, Harlow, UK
Sean Ekins ACT LLC and Collaborations In Chemistry, New York, USA
Hans-Peter Fischer GeneData, Basel, Switzerland
Peter Ghazal  University of Edinburgh, Edinburgh, UK
Christopher M. Hill Organon, Newhouse, UK
Nick Hird Takeda Chemical Industries, Osaka, Japan
Enoch Huang Pfizer, Cambridge, USA
Thomas Joos University of Tuebingen, Reutlingen, Germany
Vincent H.L. Lee Chinese University of Hong Kong, Shatin, Hong Kong
David Lewin Yale University, Branford, USA
Christopher A. Lipinski Melior Discovery, Exton, USA
Lorenz Mayr Novartis, Basel, Switzerland
Nick Meanwell Bristol-Myers Squibb, Wallingford, USA
Mark Murcko Vertex Pharmaceuticals, Cambridge, USA
Fajun Nan Shanghai Institute of Materia Medica,Shanghai, China
Gitte Neubauer Cellzome, Heidelberg, Germany
Eric Neumann  Teranode, Seattle, USA
Tim Peakman UK Biobank, Manchester, UK
Norton Peet North Andover, USA
Manuel Peitsch  Novartis, Basel, Switzerland
Kurt Rasmussen Eli Lilly, Indianapolis, USA
Janice Reichert Tufts Center for the Study of Drug Development, Boston, USA
John Reidhaar-Olson Hoffmann–La Roche, Nutley, USA
Mike Romanos GlaxoSmithKline, Stevenage, UK
Raymond C. Rowe Intelligensys, Stokesley, UK
Andreas Russ University of Oxford, Oxford, UK
Esther Schmid Pfizer, Sandwich, UK
Jonathan Sheldon Inforsense, Abingdon, UK
Michael Snyder Yale University, New Haven, USA
Susie Stephens Eli Lillyand Co. Ltd., USA
Robert Strausberg The J. Craig Venter Institute, Rockville, USA
Donny Strosberg Scripps Institute Florida, Jupiter, USA
Yuichi Sugiyama University of Tokyo, Tokyo, Japan
David Szymkowski Xencor, Monrovia, USA
Nick Terrett Pfizer, Sandwich, UK
Vladimir Torchilin Northeastern University, Boston, USA
Mark Whittaker Evotec OAI, Abingdon, UK
Hans Winkler Johnson and Johnson, Beerse, Belgium
Limsoon Wong  Laboratories for Information Technology (LIT), Singapore
X.F. Steven Zheng Robert Wood Johnson Medical School, Piscataway, USA